Zobrazeno 1 - 10
of 44
pro vyhledávání: '"Peter N.R. Heseltine"'
Autor:
Peter N.R. Heseltine, Albert E. Yellin, Stanford S. Jhee, Maria D. Appleman, Mark A. Gill, Thomas V. Berne
Publikováno v:
Clinical Therapeutics. 17:126-135
Costs involved in using piperacillin 4 g/tazobactam 500 mg, given as intermittent intravenous infusions every 8 hours, were compared with those for imipenem/cilastatin 500 mg, given as intermittent intravenous infusions every 6 hours, for the treatme
Autor:
Randall K. Nakahiro, Peter N.R. Heseltine, J. Farino, Mark A. Gill, Albert E. Yellin, Thomas V. Berne, Mark P. Okamoto, A. Bedikian, Maria D. Appleman
Publikováno v:
Antimicrobial Agents and Chemotherapy. 38:151-154
Noncompartmental and compartmental analyses of meropenem disposition in patients receiving 1-g intravenous intermittent infusions every 8 h were performed. Twelve patients (one woman and 11 men) participated in the meropenem pharmacokinetic analysis.
Autor:
Maria D. Appleman, Mark A. Gill, Randall K. Nakahiro, Peter N.R. Heseltine, Mark P. Okamoto, Alfred Chin, Albert E. Yellin, Thomas V. Berne
Publikováno v:
Current Therapeutic Research. 53:159-166
Cefmetazole is a new cephamycin antibiotic with a microbiologic spectrum very similar to cefoxitin. Because of its longer half-life, cefmetazole can be dosed on an every 8 hour schedule, in contrast to cefoxitin, which is usually dosed every 6 hours.
Autor:
Peter N.R. Heseltine
Publikováno v:
Infection Control & Hospital Epidemiology. 22:199-201
For almost 150 years healthcare workers have been taught that cross-infections are transmissible but not contagious and that the most effective way to prevent these cross-infections is to wash their hands before and after every patient contact.1,2 Bu
Autor:
Randall K. Nakahiro, Catherine A. Knupp, David A. Sclar, Albert E. Yellin, Mark A. Gill, Thomas V. Berne, Mark P. Okamoto, Alfred Chin, Maria D. Appleman, Peter N.R. Heseltine
Publikováno v:
Therapeutic Drug Monitoring. 14:220-225
Cefepime is a new broad-spectrum cephalosporin with activity against Staphylococcus, Streptococcus, Pseudomonas, and the Enterobacteriaceae. The purpose of this study was to measure cefepime concentrations in plasma, peritoneal fluid, bile fluid and
Autor:
Charles W. Stratton, Walid Khayr, Peter N.R. Heseltine, Charles E. Cherubin, Maria D. Appleman
Publikováno v:
Clinical Infectious Diseases. 13:1108-1114
To reassess the epidemiology and treatment of listeriosis in the United States, we reviewed greater than 120 cases of listeriosis from four medical centers in three geographically separated cities: Los Angeles County-University of Southern California
Publikováno v:
Diagnostic Microbiology and Infectious Disease. 14:311-317
In vitro susceptibility testing of Listeria monocytogenes most often reveals both ampicillin and penicillin as inhibitory as opposed to bactericidal with activity comparable to chloramphenicol and tetracycline. Yet, the former two penicillins are mor
Autor:
Peter N.R. Heseltine
Publikováno v:
Infection Control & Hospital Epidemiology. 20:595-597
Autor:
Richard B. Roberts, F. Blaine Hollinger, Wade P. Parks, Suraiya Rasheed, Jeffrey Laurence, Peter N.R. Heseltine, Robert W. Makuch, John A. Lubina, Karl M. Johnson, RibavirinLAS Collaborative Group
Publikováno v:
AIDS. 4:67-72
A double-blind, randomized, placebo-controlled trial comparing two daily doses of oral ribavirin (600 and 800 mg) and a placebo was performed at four medical centers geographically distributed throughout the USA. One hundred and sixty-four HIV-infect
Autor:
James Murray, Thomas V. Berne, Albert E. Yellin, Peter N.R. Heseltine, Howard Belzberg, Maria D. Appleman, Diane M. Citron
Fifteen multiresistant Acinetobacter baumannii isolates from patients in intensive care units and 14 nonoutbreak strains were tested to determine in vitro activities of nontraditional antimicrobials, including cefepime, meropenem, netilmicin, azithro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::722b79279543d65e67b0675783ef6e85
https://europepmc.org/articles/PMC89809/
https://europepmc.org/articles/PMC89809/